Reducing Chemoradiotherapy And Radiation With Targeted Immunotherapy in Children, Adolescents and Young Adults With Lymphoma

• Status: Recruiting
• Trial end date: 2028-06-30

Summary

The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (cHL).

• Phase: Phase 2

Details

• Lead Sponsor: New York Medical College
• Treatments: Cytarabine; Etoposide